Nonetheless, the systemic infusion of IGF-I causes negative collateral effects, such as hypoglycemia, hypotension, edema and tachycardia [199], the latter probably occurring as a result of the onset of hypoglycemia and/or hypotension. This evidence concerns the gene IGF1 and Hypoglycemia.